secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avidity Biosciences, Inc. (—)
CIK:        0001599901
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-079570
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avidity Biosciences completes Novartis merger for $72/share; SpinCo distributed 1:10
--------------------------------------------------------------------------------

- Merger closed Feb 27, 2026; each Avidity share converted into $72 cash, no interest.
- Prior to merger, Avidity spun off Atrium Therapeutics (SpinCo) at ratio of 1 SpinCo share per 10 Avidity shares.
- Avidity common stock to be delisted from Nasdaq; Form 25 filed, registration termination planned.
- All directors and executive officers removed; replaced by Novartis appointees (Jaime Huertas, Eduard Marti, John McKenna).
- Outstanding equity awards cashed out at $72 per share; New Hire RSUs converted into cash awards with service vesting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599901/000119312526079570/0001193125-26-079570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599901/000119312526079570/d90931d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-079570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer